Hillhouse Capital Leads $35M Series B+ Round In Hangzhou Just Biotherapeutics

Login to View

Beijing and Hong Kong-based investment firm Hillhouse Capital has led a US$35 million series B+ round in antibody and recombinant protein biotherapeutics firm Hangzhou Just Biotherapeutics (HJB).

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY

Please enter your comment!
Please enter your name here